Monday November 23 2009 | Biotechnology feed | All feeds
|
|
LifeCycle Pharma
Download detailed PDF Members: LifeCycle Pharma was founded in June 2002 as a spin-off from H. Lundbeck A/S. Its investors include H. Lundbeck A/S, Novo A/S, Nordic Biotech, Alta Partners (USA), and Adamant Biomedical Investments (Switzerland) as well as the LifeCycle Pharma executives. LifeCycle Pharma utilizes its proprietary Meltdose® technology to improve the bioavailability of known and established compounds so that patients can absorb them more effectively. LifeCycle Pharma's late-stage pipeline contains five products in clinical trials, of which the first - the cholesterol-lowering LCP-FenoChol® - is expected to reach the market in 2007.LifeCycle Pharma's strength is in selecting high-value drugs with absorbtion issues, improving their formulations, and taking them to the market in short time frames, thus substantially reducing risk as compared with other pharma and biotech companies.
This page has been viewed 245 times since April 2007, the link to the organisation's website has been followed 62 times Recent Search Terms used to find this page: meltdose patent 7217431 | lifecycle_pharma | . Search for more companies in Hørsholm This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for LifeCycle Pharma | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|